Figure 1.

The effect of LOX pathway inhibitors on neurogenic and SP-induced oedema. RWJ 63556 (1 mg kg⁻¹ i.v.), Rev 5901 (1 mg kg⁻¹ i.v.), AA 861 (0.1 mg kg⁻¹ i.v.), MK 886 (10 μg kg⁻¹ i.v.), or ethacrynic acid (1 mg kg⁻¹ i.v.) were injected 15 min before a 5-min stimulation (neurogenic oedema). RWJ 63556 (1 μg site⁻¹ i.d.), Rev 5901 (1 μg site⁻¹ i.d.), AA 861 (1 μg site⁻¹ i.d.), MK 886 (1 μg site⁻¹ i.d.), or ethacrynic acid (1 μg site⁻¹ i.d.) were co-injected with SP (100 pmol site⁻¹; SP-induced oedema). The anti-inflammatory effects are expressed as per cent inhibition of the oedema volume compared to untreated animals (see Methods). Asterisks indicate significant differences in volumes of neurogenic or SP-induced oedema between treated and untreated animals. (^*P<0.05, ^***P<0.001 according to ANOVA, followed by Bonferroni's test for multiple comparisons).